SGMT – sagimet biosciences inc. - series a (US:NASDAQ)
Stock Stats
News
Sagimet Biosciences Announces Participation in Two Upcoming Investor Conferences
Sagimet Biosciences (NASDAQ:SGMT) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $29.00 price target on the stock.
Sagimet Biosciences (NASDAQ:SGMT) is now covered by analysts at Guggenheim. They set a "buy" rating and a $27.00 price target on the stock.
Sagimet Announces Positive 52-Week Data from License Partner Ascletis’ Open-Label Phase 3 Clinical Trial Evaluating the Long-Term Safety of ASC40 (Denifanstat) Tablets in Patients with Moderate to Severe Acne
Sagimet's Denifanstat: China Phase III Safety Data Isn't A Negative Signal [Seeking Alpha]
Form 8-K Sagimet Biosciences Inc. For: Feb 02
Form SCHEDULE 13G/A Sagimet Biosciences Inc. Filed by: KPCB PANDEMIC & BIO DEFENSE FUND LLC
Form 8-K Sagimet Biosciences Inc. For: Dec 18
Form 8-K Sagimet Biosciences Inc. For: Dec 17
Form 4 Sagimet Biosciences Inc. For: Nov 20 Filed by: Kemble George
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.